Olivia Brayer
Stock Analyst at Cantor Fitzgerald
(3.16)
# 891
Out of 4,829 analysts
100
Total ratings
45.61%
Success rate
1.47%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Olivia Brayer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical | Reiterates: Overweight | $90 | $61.37 | +46.65% | 15 | Feb 20, 2025 | |
| VRTX Vertex Pharmaceuticals | Reiterates: Overweight | $480 | $439.37 | +9.25% | 22 | Feb 11, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $50 → $55 | $48.18 | +14.16% | 9 | Feb 4, 2025 | |
| GILD Gilead Sciences | Reiterates: Neutral | $80 | $103.82 | -22.94% | 10 | Dec 11, 2024 | |
| OMER Omeros | Reiterates: Neutral | n/a | $3.80 | - | 1 | Nov 14, 2024 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Neutral | $1,015 | $575.63 | +76.33% | 8 | Oct 23, 2024 | |
| AMGN Amgen | Reiterates: Overweight | $405 | $274.76 | +47.40% | 2 | Oct 22, 2024 | |
| ALNY Alnylam Pharmaceuticals | Reiterates: Neutral | $220 | $270.19 | -18.58% | 23 | Oct 11, 2024 | |
| AUPH Aurinia Pharmaceuticals | Reiterates: Overweight | $10 | $8.12 | +23.15% | 5 | Sep 16, 2024 | |
| MNKD MannKind | Reiterates: Overweight | $6.5 | $4.81 | +35.14% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $37.59 | +91.54% | 1 | Apr 13, 2023 |
BioMarin Pharmaceutical
Feb 20, 2025
Reiterates: Overweight
Price Target: $90
Current: $61.37
Upside: +46.65%
Vertex Pharmaceuticals
Feb 11, 2025
Reiterates: Overweight
Price Target: $480
Current: $439.37
Upside: +9.25%
Bristol-Myers Squibb Company
Feb 4, 2025
Maintains: Neutral
Price Target: $50 → $55
Current: $48.18
Upside: +14.16%
Gilead Sciences
Dec 11, 2024
Reiterates: Neutral
Price Target: $80
Current: $103.82
Upside: -22.94%
Omeros
Nov 14, 2024
Reiterates: Neutral
Price Target: n/a
Current: $3.80
Upside: -
Regeneron Pharmaceuticals
Oct 23, 2024
Reiterates: Neutral
Price Target: $1,015
Current: $575.63
Upside: +76.33%
Amgen
Oct 22, 2024
Reiterates: Overweight
Price Target: $405
Current: $274.76
Upside: +47.40%
Alnylam Pharmaceuticals
Oct 11, 2024
Reiterates: Neutral
Price Target: $220
Current: $270.19
Upside: -18.58%
Aurinia Pharmaceuticals
Sep 16, 2024
Reiterates: Overweight
Price Target: $10
Current: $8.12
Upside: +23.15%
MannKind
May 9, 2024
Reiterates: Overweight
Price Target: $6.5
Current: $4.81
Upside: +35.14%
Apr 13, 2023
Initiates: Overweight
Price Target: $72
Current: $37.59
Upside: +91.54%